Comparative Pharmacology
Head-to-head clinical analysis: ANGIOVIST 282 versus MAGNEVIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGIOVIST 282 versus MAGNEVIST.
ANGIOVIST 282 vs MAGNEVIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiovist 282 (diatrizoate meglumine and diatrizoate sodium) is a radiographic contrast agent that contains iodine, which attenuates X-rays, allowing visualization of vascular structures and organs. It increases the contrast between blood vessels and surrounding tissues by absorbing X-rays.
Gadopentetate dimeglumine is a paramagnetic contrast agent that shortens T1 and T2 relaxation times in tissues where it accumulates, enhancing signal intensity on T1-weighted magnetic resonance imaging (MRI). It distributes extracellularly and does not cross the intact blood-brain barrier, but accumulates in areas of disrupted barrier or abnormal vascularity.
Iohexol (ANGIOVIST 282) is a nonionic iodinated contrast medium. Typical adult dose: 50-200 mL intravenously or intra-arterially, depending on procedure (e.g., CT: 75-150 mL IV).
0.2 mL/kg (0.1 mmol/kg) intravenously, up to 0.6 mL/kg (0.3 mmol/kg) for certain indications, with a maximum of 20 mL per dose.
None Documented
None Documented
Terminal elimination half-life: 1.5–2 hours in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life in patients with normal renal function is approximately 1.6 hours. In patients with impaired renal function, half-life is prolonged (up to 30 hours with GFR <30 mL/min).
Renal excretion via glomerular filtration; unchanged drug: >95% within 24 hours. Biliary/fecal: <5%.
Renal excretion of unchanged gadopentetate dimeglumine accounts for approximately 99% of the administered dose within 72 hours. Biliary/fecal excretion is negligible (<0.5%).
Category C
Category C
Contrast Agent
Contrast Agent